key: cord-0330504-v10n0tgg authors: Eadon, M. T.; Maddatu, J.; Moe, S. M.; Sinha, A. D.; Melo Ferreira, R.; Miller, B. W.; Sher, S. J.; Su, J.; Pratt, V. M.; Chapman, A. B.; Skaar, T. C.; Moorthi, R. N. title: Pharmacogenomics of hypertension in chronic kidney disease: the CKD-PGX study date: 2021-04-06 journal: nan DOI: 10.1101/2021.03.30.21254665 sha: 8a618cb9f02490a7a51bfdbfb8bf3fafec2387c4 doc_id: 330504 cord_uid: v10n0tgg Background: Patients with chronic kidney disease (CKD) often have uncontrolled hypertension despite polypharmacy. Pharmacogenomic drug-gene interactions (DGIs) may impact the metabolism or efficacy of antihypertensive agents. We hypothesized that providing a panel of 11 pharmacogenomic predictors of antihypertensive response would improve hypertension control. Methods: A prospective cohort with CKD and hypertension was followed to assess the effect of pharmacogenomic testing on blood pressure control. The analysis population included 382 hypertensive subjects genotyped for cross-sectional assessment of drug-gene interactions and 335 subjects followed for 1 year to assess systolic (SBP) and diastolic blood pressure (DBP). Results: Most participants (58.2%) with uncontrolled hypertension had a DGI reducing the efficacy of one or more antihypertensive agents. Subjects with a DGI had 1.88-fold (95% CI 1.2-2.8) higher odds of uncontrolled hypertension as compared to those without a DGI, adjusted for race and CKD grade. CYP2C9 reduced metabolism genotypes were associated with losartan response and uncontrolled hypertension (Odds Ratio 5.2, CI 1.9 -14.7). CYP2D6 intermediate or poor metabolizers had less frequent uncontrolled hypertension compared to normal metabolizers taking metoprolol or carvedilol (OR 0.55, CI 0.3-0.95). In 335 subjects completing 1 year follow-up, SBP (-4.0 mmHg, CI 1.6- 6.5) and DBP (-3.3 mmHg, CI 2.0-4.6) were improved. The magnitude of reductions in SBP (-14.8 mmHg, CI 10.3-19.3) and DBP (-8.4 mmHg, CI 5.9-10.9) were greatest in the 90 individuals with uncontrolled hypertension and an actionable genotype. Conclusions: There is a potential role for the addition of pharmacogenomic testing to optimize antihypertensive regimens in patients with CKD. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2021. q u e s t i o n s u r v e y a t b a s e l i n e ( S u p p l e m e n t a l D o c u m e n t S 1 ) , 2 ) e a c h p r o v i d e r ( N = 7 6 ) c o m p l e t e d a b a s e l i n e 3 4 s u r v e y r e g a r d i n g t h e i r a t t i t u d e t o w a r d t h e t e s t i n g 1 6 , a n d 3 ) e a c h p r o v i d e r c o m p l e t e d a r e t u r n o f r e s u l t s s u r v e y 3 5 f o r e v e r y o n e o f t h e i r e n r o l l e d p a t i e n t s t o q u e r y w h e t h e r t h e y b e l i e v e d t e s t i n g a f f e c t e d t h e i r c l i n i c a l 3 6 m a n a g e m e n t . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A t o t a l o f 4 7 2 a d u l t s u b j e c t s w e r e r e c r u i t e d a n d c o n s e n t e d f r o m o u t p a t i e n t n e p h r o l o g y c l i n i c s w i t h i n t h e 6 6 I n d i a n a U n i v e r s i t y H e a l t h s y s t e m , t h e E s k e n a z i H e a l t h s a f e t y -n e t s y s t e m , a n d a s s o c i a t e d o u t l y i n g s u b u r b a n 6 7 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2021. ; v a r i a n t t h a t p r e d i c t e d r e d u c e d e f f i c a c y o f a n a n t i -h y p e r t e n s i v e a g e n t t h a t t h e y w e r e p r e s c r i b e d a t b a s e l i n e . 9 7 9 8 I n d i v i d u a l d r u g -g e n e a n a l y s e s 9 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. b j e c t s c o m p l e t e d a b a s e l i n e s u r v e y . S u p p l e m e n t a l F i g u r e 1 i l l u s t r a t e s t h e r e s p o n s e f r o m s e l e c t e d q u e s t i o n s 3 0 r e g a r d i n g s u b j e c t s ' a t t i t u d e t o w a r d g e n e t i c t e s t i n g . T h e s u r v e y s r e v e a l e d t h a t f e w s u b j e c t s ( 5 . 4 % ) w e r e 3 1 f a m i l i a r w i t h t h e t e r m s " p h a r m a c o g e n o m i c s , g e n e t i c t e s t i n g o r p e r s o n a l i z e d m e d i c i n e " . M o r e t h a n 9 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2021. ; n t i h y p e r t e n s i v e m e d i c a t i o n r e s p o n s e i s f r e q u e n t l y u n p r e d i c t a b l e a n d v a r i e s a m o n g i n d i v i d u a l s . I n C K D , b l o o d 3 9 p r e s s u r e c o n t r o l a t r e c o m m e n d e d t a r g e t s i s c l e a r l y i m p o r t a n t t o p r e v e n t c a r d i o v a s c u l a r d i s e a s e a n d e n d o r g a n 4 0 d y s f u n c t i o n . H o w e v e r , 2 4 . 9 t o 3 3 . 4 % o f i n d i v i d u a l s w i t h g r a d e 3 o r g r e a t e r C K D h a v e u n c o n t r o l l e d B P d e s p i t e 4 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. o n c e n t r a t i o n s o f m e t o p r o l o l , y e t a s u b j e c t w i t h a r e d u c e d f u n c t i o n v a r i a n t o f A D R B 1 w o u l d h a v e t h e o p p o s i t e 7 2 p r e d i c t e d e f f i c a c y . T h e r e i s i n s u f f i c i e n t e v i d e n c e t o r e c o n c i l e t h e s e t w o e f f e c t s ; t h u s , a l l v a r i a n t s w e r e 7 3 r e p o r t e d s e p a r a t e l y a n d t h e p r e s c r i b i n g c l i n i c i a n d e c i d e d h o w t h e y w o u l d u s e t h e i n f o r m a t i o n . C o n s i d e r a t i o n 7 r m a c o g e n o m i c d a t a t o m a k e c h o i c e s i n a n t i h y p e r t e n s i v e r e g i m e n s . W e e x p e c t t h a t i n t h e f u t u r e , w h o l e 0 5 g e n o m e o r e x o m e s e q u e n c i n g w i l l b e i n t e g r a t e d i n t o t h e c l i n i c a l s e t t i n g . A t t h a t t i m e , g e n o t y p e i n f o r m a t i o n 0 6 w i l l b e r e a d i l y a v a i l a b l e t o p r o v i d e r s a n d w i l l u s h e r i n a n e x c i t i n g e r a i n t h e c a r e o f p a t i e n t s w i t h h y p e r t e n s i o n 0 7 a n d c h r o n i c k i d n e y d i s e a s e . 0 8 0 9 1 0 1 1 1 2 1 3 1 4 1 5 A u t h o r c o n t r i b u t i o n s : C o n c e p t i o n , s t u d y d e s i g n : M T E , R N M , A B C , T C S , S M M 1 6 A n a l y s i s , i n t e r p r e t a t i o n o f d a t a : M T E , R N M , J M , S M M , R M F , J S . C o n d u c t o f s t u d y : V M P , M T E 1 7 D r a f t i n g / r e v i s i n g t h e a r t i c l e : M T E , R N M , J M . P r o v i d i n g i n t e l l e c t u a l c o n t e n t : A D S , B W M , S J S . F i n a l a p p r o v a l o f 1 F i g u r e 1 : E n r o l l m e n t a n d i n c l u s i o n i n t h e a n a l y s e s . S u r v e y d a t a w a s a v a i l a b l e i n 4 3 5 a d u l t p a r t i c i p a n t s w h o 4 4 r e c e i v e d t h e p h a r m a c o g e n o m i c g e n o t y p i n g p a n e l . T h e r e w e r e 3 8 2 s u b j e c t s w h o h a d a h y p e r t e n s i o n d i a g n o s i s 4 5 a n d w e r e p r e s c r i b e d 1 o r m o r e a n t i h y p e r t e n s i v e s . T h e s e 3 8 2 w e r e i n c l u d e d i n t h e c r o s s -s e c t i o n a l a n a l y s i s . I n 4 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2021. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Hypertension Prevalence Among Adults Aged 18 and Over: United States Hypertension in chronic kidney disease: navigating the evidence Hypertension in CKD: Core Curriculum Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects I: Cozaar prescribing information Genotype-Guided Hydralazine Therapy A Physiologic Approach to the Pharmacogenomics of Hypertension Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study Prevalence of Apparent Treatment-Resistant Hypertension in the United States Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy A new equation to estimate glomerular filtration rate Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance Prevalence of apparent treatment-resistant hypertension among individuals with CKD ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines evidencebased guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) BiDil prescribing information Corporation NP: Lopressor Prescribing Information United States Food and Drug Administration Pharmacogenetics: from bench to byte--an update of guidelines Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor Clinical pharmacokinetics of losartan Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174 Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases CYP2C9 genetic variants and losartan oxidation in a Turkish population Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure Pharmacogenetic Associations of beta1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes) Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol G protein receptor kinase 4 polymorphisms: beta-blocker pharmacogenetics and treatment-related outcomes in hypertension G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression